Literature DB >> 28574598

Integrin-Linked Kinase Regulates Bone Formation by Controlling Cytoskeletal Organization and Modulating BMP and Wnt Signaling in Osteoprogenitors.

Marian Dejaeger1, Anna-Marei Böhm1, Naomi Dirckx1, Joke Devriese1, Elena Nefyodova1, Ruben Cardoen1, René St-Arnaud2, Jos Tournoy3,4, Frank P Luyten5, Christa Maes1.   

Abstract

Cell-matrix interactions constitute a fundamental aspect of skeletal cell biology and play essential roles in bone homeostasis. These interactions are primarily mediated by transmembrane integrin receptors, which mediate cell adhesion and transduce signals from the extracellular matrix to intracellular responses via various downstream effectors, including integrin-linked kinase (ILK). ILK functions as adaptor protein at focal adhesion sites, linking integrins to the actin cytoskeleton, and has been reported to act as a kinase phosphorylating signaling molecules such as GSK-3β and Akt. Thereby, ILK plays important roles in cellular attachment, motility, proliferation and survival. To assess the in vivo role of ILK signaling in osteoprogenitors and the osteoblast lineage cells descending thereof, we generated conditional knockout mice using the Osx-Cre:GFP driver strain. Mice lacking functional ILK in osterix-expressing cells and their derivatives showed no apparent developmental or growth phenotype, but by 5 weeks of age they displayed a significantly reduced trabecular bone mass, which persisted into adulthood in male mice. Histomorphometry and serum analysis indicated no alterations in osteoclast formation and activity, but provided evidence that osteoblast function was impaired, resulting in reduced bone mineralization and increased accumulation of unmineralized osteoid. In vitro analyses further substantiated that absence of ILK in osteogenic cells was associated with compromised collagen matrix production and mineralization. Mechanistically, we found evidence for both impaired cytoskeletal functioning and reduced signal transduction in osteoblasts lacking ILK. Indeed, loss of ILK in primary osteogenic cells impaired F-actin organization, cellular adhesion, spreading, and migration, indicative of defective coupling of cell-matrix interactions to the cytoskeleton. In addition, BMP/Smad and Wnt/β-catenin signaling was reduced in the absence of ILK. Taken together, these data demonstrate the importance of integrin-mediated cell-matrix interactions and ILK signaling in osteoprogenitors in the control of osteoblast functioning during juvenile bone mass acquisition and adult bone remodeling and homeostasis.
© 2017 American Society for Bone and Mineral Research. © 2017 American Society for Bone and Mineral Research.

Entities:  

Keywords:  ACTIN CYTOSKELETON; BONE FORMATION; CELL MIGRATION; INTEGRIN-LINKED KINASE (ILK); OSTEOBLAST; OSTEOPROGENITOR

Mesh:

Substances:

Year:  2017        PMID: 28574598     DOI: 10.1002/jbmr.3190

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  15 in total

Review 1.  Bone morphogenetic proteins in fracture repair.

Authors:  Ivo Dumic-Cule; Mihaela Peric; Lucija Kucko; Lovorka Grgurevic; Marko Pecina; Slobodan Vukicevic
Journal:  Int Orthop       Date:  2018-09-15       Impact factor: 3.075

2.  Differentially expressed proteins identified by TMT proteomics analysis in bone marrow microenvironment of osteoporotic patients.

Authors:  Q Zhou; F Xie; B Zhou; J Wang; B Wu; L Li; Y Kang; R Dai; Y Jiang
Journal:  Osteoporos Int       Date:  2019-02-09       Impact factor: 4.507

3.  Vhl deletion in osteoblasts boosts cellular glycolysis and improves global glucose metabolism.

Authors:  Naomi Dirckx; Robert J Tower; Evi M Mercken; Roman Vangoitsenhoven; Caroline Moreau-Triby; Tom Breugelmans; Elena Nefyodova; Ruben Cardoen; Chantal Mathieu; Bart Van der Schueren; Cyrille B Confavreux; Thomas L Clemens; Christa Maes
Journal:  J Clin Invest       Date:  2018-02-12       Impact factor: 14.808

Review 4.  Integrins in the Regulation of Mesenchymal Stem Cell Differentiation by Mechanical Signals.

Authors:  Lei Wang; Fuwen Zheng; Ruixue Song; Lequan Zhuang; Ming Yang; Jian Suo; Lisha Li
Journal:  Stem Cell Rev Rep       Date:  2021-09-18       Impact factor: 5.739

Review 5.  Osteogenesis imperfecta and therapeutics.

Authors:  Roy Morello
Journal:  Matrix Biol       Date:  2018-03-11       Impact factor: 11.583

6.  Participation of integrin β3 in osteoblast differentiation induced by titanium with nano or microtopography.

Authors:  Helena B Lopes; Gileade P Freitas; Carlos N Elias; Coralee Tye; Janet L Stein; Gary S Stein; Jane B Lian; Adalberto L Rosa; Marcio M Beloti
Journal:  J Biomed Mater Res A       Date:  2019-02-23       Impact factor: 4.396

7.  Identification of potential therapeutic targets of deer antler extract on bone regulation based on serum proteomic analysis.

Authors:  Baojin Yao; Hongwei Gao; Jia Liu; Mei Zhang; Xiangyang Leng; Daqing Zhao
Journal:  Mol Biol Rep       Date:  2019-07-08       Impact factor: 2.316

8.  Integrin alpha11 is an Osteolectin receptor and is required for the maintenance of adult skeletal bone mass.

Authors:  Bo Shen; Kristy Vardy; Payton Hughes; Alpaslan Tasdogan; Zhiyu Zhao; Rui Yue; Genevieve M Crane; Sean J Morrison
Journal:  Elife       Date:  2019-01-11       Impact factor: 8.140

9.  Therapeutic effect of integrin-linked kinase gene-modified bone marrow-derived mesenchymal stem cells for streptozotocin-induced diabetic cystopathy in a rat model.

Authors:  Yi Huang; Jie Gao; Yiduo Zhou; Shuo Wu; Yunpeng Shao; Haoliang Xue; Baixin Shen; Liucheng Ding; Zhongqing Wei
Journal:  Stem Cell Res Ther       Date:  2020-07-10       Impact factor: 6.832

10.  Integrin-linked kinase controls retinal angiogenesis and is linked to Wnt signaling and exudative vitreoretinopathy.

Authors:  Hongryeol Park; Hiroyuki Yamamoto; Lucas Mohn; Lea Ambühl; Kenichi Kanai; Inga Schmidt; Kee-Pyo Kim; Alessia Fraccaroli; Silke Feil; Harald J Junge; Eloi Montanez; Wolfgang Berger; Ralf H Adams
Journal:  Nat Commun       Date:  2019-11-20       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.